Searching over 5,500,000 cases.


searching
Buy This Entire Record For $7.95

Official citation and/or docket number and footnotes (if any) for this case available with purchase.

Learn more about what you receive with purchase of this case.

GlaxoSmithKline, LLC v. Genentech, Inc.

United States District Court, Third Circuit

August 22, 2013

GLAXOSMITHKLINE, LLC, Plaintiff,
v.
GENENTECH, INC., Defendant.

ORDER CONSTRUING THE TERMS OF U.S. PATENT, RE41, 555

Order After having considered the submissions of the parties and hearing oral argument on the matter, IT IS HEREBY ORDERED, ADJUDGED, and DECREED that, as used in the asserted claims of US. Patent No. RE41.555 ("the '555 Patent")[1]:

1. The term "selectively eluting [the monomeric IgG antibody] from the support" and "the antibody selectively eluted" is construed to mean "eluting such that the concentration of contaminants in the mixture relative to the concentration of monomeric IgG antibody is lower compared to what is applied to the column."[2]

2. The term " monomeric IgG antibody" is construed to mean "a monomeric IgG antibody or a monomeric IgG antibody-like protein which may be purified by the protocol described therein."[3]


Buy This Entire Record For $7.95

Official citation and/or docket number and footnotes (if any) for this case available with purchase.

Learn more about what you receive with purchase of this case.